Novel drugs for the treamtment of diabetes

May 29, 2003

A new approach to providing medication for adult diabetics (type 2 diabetes) that is not dependent on insulin has been developed by a doctoral student at the Hebrew University of Jerusalem. For his work, which he did for his Ph.D. thesis in pharmacology, Arie Gruzman was awarded one of this year's Kaye Innovation Awards at the Hebrew University.

Unlike other conventional drugs that require active insulin-producing cells in the pancreas and that often fail to overcome a companion problem of insulin resistance, the novel compounds developed by Gruzman and his supervisor, Prof. Shlomo Sasson, in collaboration with Prof. Yehoshua Katzhendler and Prof. Erol Cerasi of the Hebrew University School of Pharmacy and the Faculty of Medicine, are unique in that they can reduce hyperglycemia (above-normal levels of glucose in the blood) by increasing the rate of glucose disposal in the blood in a non-insulin-dependent manner.

The new drugs, when fully developed, may provide a treatment to diabetic patients who have especially serious problems of insufficient natural insulin production and/or resistance to insulin.

A patent for these new compounds - which, perhaps surprisingly, are based on D-Xylose, a sugar found in fruits -- has been obtained through the Hebrew University's Yissum Research Development Company. The laboratory work was supported financially by the Deutsch Foundation of Venezuela and the Nophar Program of the Israel Ministry of Trade and Industry.

Gruzman, 32, was born in Russia and studied at a medical institute in his home town of Nizhny Novogrod. He immigrated to Israel 12 years ago and earned a B.Sc.degree in pharmaceutical chemistry at Bar-Ilan University, after which he began his graduate studies at the Hebrew University. He is married to another immigrant from the former U.S.S.R., who is a graduate student at the Hebrew University Faculty of Medicine, and they are the parents of two daughters.

The Kaye Innovation Awards at the Hebrew University have been awarded annually since 1994. Isaac Kaye of England, a prominent industrialist in the pharmaceutical industry, established the awards to encourage faculty, staff, and students of the university to develop innovative methods and inventions with good commercial potential which have benefited or will benefit the university and society. The Kaye Innovation Awards at the Hebrew University were awarded on May 27, during the 66th meeting of the University Board of Governors.
-end-


The Hebrew University of Jerusalem

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.